ACRV Stock Overview
A clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Acrivon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.18 |
| 52 Week High | US$12.89 |
| 52 Week Low | US$3.19 |
| Beta | 0 |
| 11 Month Change | 0.70% |
| 3 Month Change | -18.13% |
| 1 Year Change | -38.10% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.85% |
Recent News & Updates
Recent updates
Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?
Jul 17
Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation
Mar 29Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Oct 05Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Jun 22We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth
Feb 22Shareholder Returns
| ACRV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.1% | -2.2% | -2.3% |
| 1Y | -38.1% | 13.9% | 16.7% |
Return vs Industry: ACRV underperformed the US Biotechs industry which returned 11.5% over the past year.
Return vs Market: ACRV underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| ACRV volatility | |
|---|---|
| ACRV Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ACRV's share price has been volatile over the past 3 months.
Volatility Over Time: ACRV's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 60 | Peter Blume-Jensen | www.acrivon.com |
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer.
Acrivon Therapeutics, Inc. Fundamentals Summary
| ACRV fundamental statistics | |
|---|---|
| Market cap | US$215.83m |
| Earnings (TTM) | -US$64.12m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs ACRV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACRV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$64.12m |
| Earnings | -US$64.12m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACRV perform over the long term?
See historical performance and comparison